文献速递炎症性肠病

较短病程与克罗恩病患者对维得利珠单抗更高应答率相关,但溃疡性结肠炎患者无此关联

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-01-06

这项回顾性多中心队列分析纳入2014年5月至2016年12月接受维得利珠单抗治疗的克罗恩病(n=650)和溃疡性结肠炎(n=437)患者,按病程≤2年与>2年分层。克罗恩病早期组6个月内临床缓解、无激素缓解和内镜缓解率均显著高于晚期组,校正后仍显著;溃疡性结肠炎中病程不是应答的显著预测因素。

要点

  • 克罗恩病病程≤2年者6个月内临床缓解38% vs 23%,无激素缓解43% vs 14%,内镜缓解29% vs 13%,均P<.05。
  • 校正包括既往TNF拮抗剂暴露等因素后,早期克罗恩病临床缓解aHR 1.59(95%CI 1.02-2.49)。
  • 溃疡性结肠炎中病程不是维得利珠单抗应答的显著预测因素。

核心结论

  • 克罗恩病病程≤2年者接受维得利珠单抗后达到临床缓解、无激素缓解和内镜缓解的可能性显著高于病程>2年者;溃疡性结肠炎中病程与维得利珠单抗应答无关。

研究设计与样本

  • 回顾性多中心 consortium 分析,纳入2014年5月至2016年12月接受维得利珠单抗治疗的克罗恩病患者650例和溃疡性结肠炎患者437例。
  • 采用时间至事件分析比较病程≤2年(早期)与>2年(晚期)患者的临床缓解、无激素缓解(CSFR)和内镜缓解率,并用Cox比例风险模型识别与结局相关的因素。

主要发现

  • 维得利珠单抗治疗启动6个月内,早期克罗恩病 vs 晚期克罗恩病:临床缓解38% vs 23%,无激素缓解43% vs 14%,内镜缓解29% vs 13%(所有比较P<.05)。
  • 校正包括既往TNF拮抗剂暴露等疾病相关因素后,早期克罗恩病较晚期克罗恩病更可能达到临床缓解(aHR 1.59;95%CI 1.02-2.49)、无激素缓解(aHR 3.39;95%CI 1.66-6.92)和内镜缓解(aHR 1.90;95%CI 1.06-3.39)。
  • 在溃疡性结肠炎患者中,病程不是应答的显著预测因素。

关键数值与推荐

  • 早期病程定义为病程≤2年,晚期病程定义为病程>2年。
  • 主要结局为临床缓解、无激素缓解(CSFR)和内镜缓解。
  • 校正因素包括既往TNF拮抗剂暴露等疾病相关因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. METHODS: We analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes. RESULTS: Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02-2.49), CSFR (aHR, 3.39; 95% CI, 1.66-6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06-3.39). In contrast, disease duration was not a significant predictor of response among patients with UC. CONCLUSIONS: Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Faleck DM, Winters A, Chablaney S, et al. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019. PMID: 30625408. doi:10.1016/j.cgh.2018.12.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。